glp 1 agonists in development Discover How GLP-1 Trials Are Not One-Size-Fit-All glp-1_analogs [TUSOM | Pharmwiki]

R.DenyerM.et al (2019)

However, treatment suitability depends on: Medical history Skin condition Fat thickness Allergies Liver health Patients who are pregnant, breastfeeding, or managing certain medical conditions may not be suitable candidates

11 In a 12-week clinical study, a novel, topical facial serum containing 3% TXA, 1% kojic acid, and 5% niacinamide was evaluated for its effectiveness in treating melasma, PIH, and hyperpigmentation in Brazilian female subjects with Fitzpatrick skin types I-IV

In this review, we explore the progress and challenges of using PDCOs in treatment decision-making for digestive system cancers

Key Takeaways CagriSema and Retatrutide are both investigational: Neither is FDA-approved for obesity or diabetes treatment as of May 2026